Diabetes, Vol 37, Issue 10 1386-1391, Copyright © 1988 by American Diabetes Association

ARTICLES

Opposite effects of insulin and catecholamines on LDL-receptor activity in human mononuclear leukocytes

W Krone, H Naegele, B Behnke and H Greten
Medizinische Kernklinik und Poliklinik, Universitats-Krankenhaus Eppendorf, Hamburg, Federal Republic of Germany.

The mechanisms by which insulin and catecholamines affect low-density lipoprotein (LDL)-receptor activity were studied in freshly isolated human mononuclear leukocytes. Incubation of cells for up to 24 h in a lipid-free medium resulted in an increase in the specific binding, accumulation, and degradation of 125I-labeled LDL. Insulin stimulated the ability of the cells to bind, accumulate, and degrade the lipoprotein with high affinity, which may be caused by an increase in the LDL-receptor number without altering binding affinity. (-)-Epinephrine inhibited the specific binding, accumulation, and degradation of 125I-LDL. This effect appears to be mediated by a decrease in the number of LDL receptors and not by a change in the binding affinity. (-)-Norepinephrine, the unspecific beta-adrenergic agonist (-)-isoproterenol, and the beta 2-specific agonist terbutaline mimicked the effect of epinephrine on LDL-receptor activity. Catecholamines and beta-adrenergic agonists yielded sigmoidal log-concentration effect curves. The action of epinephrine was attenuated by the beta-antagonist (dl)-propranolol. These results demonstrate that insulin stimulates and catecholamines suppress the specific binding, accumulation, and degradation of 125I-LDL in human mononuclear leukocytes. The catecholamine action appears to be mediated by beta 2-adrenergic receptors. A suppression of LDL-receptor activity resulting from deficiency of insulin and elevated plasma catecholamine concentrations in uncontrolled insulin-dependent diabetic patients may contribute to the increased levels of LDL cholesterol observed in these patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Kotzka, D. Müller-Wieland, G. Roth, L. Kremer, M. Munck, S. Schürmann, B. Knebel, and W. Krone Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade J. Lipid Res., January 1, 2000; 41(1): 99 - 108. [Abstract] [Full Text]

				K. Saku, B. Zhang, K. Shirai, S. Jimi, K. Yoshinaga, and K. Arakawa Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1443 - 1451. [Abstract] [Full Text] [PDF]

				S. M. Haffner The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease Endocr. Rev., October 1, 1998; 19(5): 583 - 592. [Abstract] [Full Text]

				M. P. Stern The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes Arch Fam Med, March 1, 1998; 7(2): 155 - 162. [Abstract] [Full Text] [PDF]

				Rüd. Streicher, Jör. Kotzka, D. Müller-Wieland, G. Siemeister, M. Munck, H. Avci, and W. Krone SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I J. Biol. Chem., March 22, 1996; 271(12): 7128 - 7133. [Abstract] [Full Text] [PDF]

				P. Zunker, A. Schick, H.-C. Buschmann, D. Georgiadis, D. G. Nabavi, M. Edelmann, and E. B. Ringelstein Hyperinsulinism and Cerebral Microangiopathy Stroke, February 1, 1996; 27(2): 219 - 223. [Abstract] [Full Text]

				J. Kuusisto, L. Mykkanen, K. Pyorala, and M. Laakso Hyperinsulinemic Microalbuminuria : A New Risk Indicator for Coronary Heart Disease Circulation, February 1, 1995; 91(3): 831 - 837. [Abstract] [Full Text]